Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
GROWTH
Cosentyx® returns to growth; expecting stronger Q4
Cosentyx®
Sales evolution
USD m, % cc
Ex-US
US
1,274
+4%
1,329
Q3 performance
■▪ US sales (-3%): supported by volume growth, offset by PY base effects
◉
Ex-US sales (+15%): growth in core indications
Q4 expect stronger sales growth
■ US: continuing volume growth; lower PY base due to Q4 2022 RD true-up
"
EU: HS approved in Q2, launch on track
612
532
Life cycle management
■ US: IV formulation approved, HS approval expected Q4
742
■ 3 Ph3 studies ongoing: GCA, Polymyalgia Rheumatica, Rotator Cuff Tendinopathy
717
Q3 2022
Q3 2023
GCA
Giant Cell Arteritis. HS-hidradenitis suppurativa. IV - intravenous. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
PSA and nr-axSpA.
7 Investor Relations | Q3 2023 Results
1. for adult AS,
✓ NOVARTIS | Reimagining MedicineView entire presentation